Earnings And Revenue GrowthPEN shares are predicted to appreciate due to rising revenue and earnings estimates, along with multiple expansion driven by accelerating revenue growth.
Market ExpansionSTORM-PE is the first randomized controlled trial of mechanical thrombectomy in pulmonary embolism and should drive increased thrombectomy penetration.
New Product LaunchThe upcoming Thunderbolt launch is expected to nearly double PEN's revenue per stroke procedure, driving stronger neuro thrombectomy growth and improving gross margins.